Literature DB >> 11414362

Role of the C5b-9 complement complex in cell cycle and apoptosis.

H G Rus1, F I Niculescu, M L Shin.   

Abstract

Assembly of C5b-9 on cell membranes results in transmembrane channels and causes cell death. When the number of C5b-9 molecules is limited, nucleated cells are able to escape cell death by endocytosis and by shedding of membranes bearing C5b-9. Sublytic CSb-9 induces proto-oncogenes, activates the cell cycle, and enhances cell survival. In addition, C5b-9 reverses the differentiated phenotype of postmitotic cells, such as oligodendrocytes and skeletal muscle cells. The signal transduction pathways responsible for cell cycle activation by CSb-9 include Gi-mediated activation of extracellular signal-regulated kinase 1 and phosphatidylinositol 3-kinase (PI3-K). Cell survival enhanced by C5b-9 is mediated by the PI3-K/Akt pathway, which inhibits apoptosis through regulation of BAD. These findings indicate that complement activation and membrane assembly of sublytic C5b-9 play an important role in inflammation by promoting cell proliferation and by rescuing apoptotic cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414362     DOI: 10.1034/j.1600-065x.2001.1800104.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  33 in total

Review 1.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

2.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

Review 3.  The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription.

Authors:  Matthew Fosbrink; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway.

Authors:  Xiaohong Wu; Govind Ragupathi; Katherine Panageas; Feng Hong; Philip O Livingston
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

Review 5.  Pathogenic role of antiphospholipid antibodies.

Authors:  J E Salmon; P G de Groot
Journal:  Lupus       Date:  2008-05       Impact factor: 2.911

6.  Spontaneous complement activation on human B cells results in localized membrane depolarization and the clustering of complement receptor type 2 and C3 fragments.

Authors:  Morten Løbner; Robert G Q Leslie; Wolfgang M Prodinger; Claus H Nielsen
Journal:  Immunology       Date:  2009-01-23       Impact factor: 7.397

7.  Remarkable Activation of the Complement System and Aberrant Neuronal Localization of the Membrane Attack Complex in the Brain Tissues of Scrapie-Infected Rodents.

Authors:  Yan Lv; Cao Chen; Bao-Yun Zhang; Kang Xiao; Jing Wang; Li-Na Chen; Jing Sun; Chen Gao; Qi Shi; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2014-10-14       Impact factor: 5.590

Review 8.  The role of complement activation in atherosclerosis.

Authors:  Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 9.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

10.  Microarray reveals complement components are regulated in the serum-deprived rat retinal ganglion cell line.

Authors:  Abdelnaby Khalyfa; Timothy Chlon; He Qiang; Neeraj Agarwal; Nigel G F Cooper
Journal:  Mol Vis       Date:  2007-02-28       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.